<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8756EB88-F187-487C-A54E-9210F5ECAFA6"><gtr:id>8756EB88-F187-487C-A54E-9210F5ECAFA6</gtr:id><gtr:name>MRC Anatomical Neuropharmacology Unit</gtr:name><gtr:address><gtr:line1>Mansfield Road</gtr:line1><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 3TH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8756EB88-F187-487C-A54E-9210F5ECAFA6"><gtr:id>8756EB88-F187-487C-A54E-9210F5ECAFA6</gtr:id><gtr:name>MRC Anatomical Neuropharmacology Unit</gtr:name><gtr:address><gtr:line1>Mansfield Road</gtr:line1><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 3TH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4DB09770-AE0C-4CC3-9AB7-DE7636649565"><gtr:id>4DB09770-AE0C-4CC3-9AB7-DE7636649565</gtr:id><gtr:firstName>R</gtr:firstName><gtr:surname>Mcllhinney</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U138197108"><gtr:id>9B04F095-CF02-4610-A2F2-AE7DEF50458F</gtr:id><gtr:title>Functions and molecular characterization of novel GABAB receptor interacting proteins</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U138197108</gtr:grantReference><gtr:abstractText>In the human brain, nerve cells are activated by the amino acid, glutamic acid, whereas a related chemical, ? -amino butyric acid (GABA) is responsible for the inhibition of the activity of nerve cells. These effects are mediated by different receptor proteins that bind these chemical messengers specifically, and inform the cell about their presence in the extracellular space in the brain. The rapid responses to binding of these chemicals are caused by the opening of ion channels, whilst slower responses are the result of activating different glutamate and GABA receptors, which leads to the production of secondary messengers inside the cell. Over-stimulation, or failure to respond, of any of these receptors can lead to a variety of pathological conditions. Therefore, these receptors are important targets for therapeutic intervention in diseases such as epilepsy, anxiety, depression and neuronal death following strokes. Our research program is designed to increase our understanding of these receptors in terms of their structure, and their interactions with other proteins that can modulate their function and targeting on the surface of nerve cells. We are therefore characterising the structure of the AMPA and N-methyl-D-aspartate receptor (subtypes of the glutamate receptors) and the protein interactions of second messenger coupled receptors, focussing on the GABAB receptor.</gtr:abstractText><gtr:technicalSummary>Glutamate receptors mediate most of the fast excitatory neurotransmission in the central nervous system, whilst ?-amino butyric acid (GABA) receptors mediate inhibitory neurotransmission. Whilst both of these receptors utilize ion channels for fast signalling, they also have second messenger-coupled receptors that modulate neurotransmission on longer time scales. The ion channels opened by glutamate include the N-methyl-D aspartate (NMDA) receptor, which has an important role in learning and memory. The second messenger coupled receptors for glutamate (mGluRs) and GABA (GABAB receptor are also important therapeutic targets for a range of pathological conditions, including epilepsy, neuro-excitotoxicity, anxiety and depression. Understanding the structure and function of these receptors is, therefore, extremely important, especially as it has become apparent that they function in large molecular complexes, which can modulate their responses. This project aims to characterize the novel proteins, identified in previous studies, that contribute to these complexes for the GABAB receptor.
Previous work in the laboratory identified an important role for the N-terminal domain of the NMDA-receptor in receptor assembly. To pursue this further we have established a collaboration with Dr Radu Aricescu (Wellcome Trust Centre for Human Genetics, Oxford) who is MRC funded to examine the structures of the ionotropic glutamate receptor family. Preliminary results show that a soluble form of the domain obtained from the AMPA receptor subunit GluR2, can be crystallized, and does indeed oligomerize. This work continues and has been extended to look at interactions of other neuronal proteins.
Recently we found evidence for the association of the GABAB receptor with members of the copine family of proteins, and with the chloride transporter KCC2. Collaborative studies with Dr. Colin Akerman (Dept. Pharmacology, Oxford) has revealed that activation of the GABAB receptor causes a rapid and sustained decrease in the activity of KCC2. Currently experiments are being carried out to determine the mechanism behind this phenomenon and how it is regulated.
The copines are a relatively little studied family of proteins but two members of the family are brain specific and one, copine 6, shows evidence of neuronal activity related changes in amount. The proteins are thought to move proteins to the plasma mambrane in response to changes in intracellular calcium./ Our current work is aimed at testing this hypothesis and characterizing the function of these proteins in the brain. This will involve the use of siRNA knockdown of the proteins in cultured neurones, the production of antibodies to them and the use of mutated and domain swapped versions of the proteins to perturb their function.</gtr:technicalSummary><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1192907</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GABAB receptor research</gtr:description><gtr:id>B3E9A3CA-A77F-4924-A3FD-0A111170D257</gtr:id><gtr:impact>Several publications, and a consultancy with GSK for three years. Ongoing work from this collaboration formed part of our successful 2008 quinquennial review proposals.</gtr:impact><gtr:outcomeId>E5354461295-1</gtr:outcomeId><gtr:partnerContribution>Cell lines, cDNA clones, antibodies and other reagents. Access to instrumentation and analysis or proteomic screens</gtr:partnerContribution><gtr:piContribution>Analysis of receptor interacting proteins, and their consequences.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit to Unit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>483EDD81-A698-4503-A361-81ECCBBCB4E8</gtr:id><gtr:impact>Annual school science day in Unit where we exhibit our work and encourage discussion of science as a subject and career.

Positive feedback from teachers and students.</gtr:impact><gtr:outcomeId>BAF8A32A38D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8A8F4874-486A-4289-86DF-0C77C7481C48</gtr:id><gtr:impact>The official report on the MRC Presentations was that they ranked among the best at the Festival

Visit by Vince Cable to the Stand</gtr:impact><gtr:outcomeId>dHoL9imMHMy</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit to Unit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FC43A981-21CD-44BF-A786-53B5B81A7317</gtr:id><gtr:impact>Large number of studentys came to the laboratory and carried out some simple experiments.

Considerable enthusiasm shown for the visit and good feedback from the schools.</gtr:impact><gtr:outcomeId>KfH5UaerXx6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Schools Visit to Unit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AC49B66D-B05B-4250-9D23-56C71536DC58</gtr:id><gtr:impact>Over 50 students passed through the Laboratory and took part in practical activities and presentstions

Very positive feedback from the students on their visit</gtr:impact><gtr:outcomeId>doKYCRiSLE6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F205A9E3-3338-4152-9517-4A9B472A51A3</gtr:id><gtr:impact>Manned stand for MRC at theCheltenham Science Festival

Very Positive feedback form public</gtr:impact><gtr:outcomeId>CBF29B2D00E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6A45E75F-0971-49FA-A3C0-011AC24983D4</gtr:id><gtr:impact>Manned MRC Stand

Great interest shown in subjects and positive feedback about the presentations</gtr:impact><gtr:outcomeId>tN4KUXxLfmt</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRCT Development Gap Funding</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>33F4011C-D8AB-4848-B61F-65C2DB43AF40</gtr:id><gtr:outcomeId>9E7E414F73E0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A novel binding site in the NTD-of the AMPA receptor subunit GluR2 was discovered following a collaborative study with Dr Radu Aricescu of the Wellcome Center for Human Genetics, Oxford. Thgis followed the successful crystallization of the NTD.</gtr:description><gtr:grantRef>MC_U138197108</gtr:grantRef><gtr:id>A07CD033-0395-4E17-A722-AFD76D872BF4</gtr:id><gtr:impact>The binding site offers a potential target for novel therapeutic drugs. This possibility is being pursued using funding from the MRC Gap Funding initiative.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>E890EC38E7D</gtr:outcomeId><gtr:patentId>NULL</gtr:patentId><gtr:protection>Protection not required</gtr:protection><gtr:title>Novel Binding site in GluR2 subunit</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>01A3ABFA-B4B5-4970-BD08-0339B1B7ABCA</gtr:id><gtr:title>Identification of a novel region of the GABA(B2) C-terminus that regulates surface expression and neuronal targeting of the GABA(B) receptor.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/575e0a2595915220a4a67582c7d62d97"><gtr:id>575e0a2595915220a4a67582c7d62d97</gtr:id><gtr:otherNames>Pooler AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>h1CPxQ7NcGM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83764A86-029B-4C91-A14E-7CDFBDA5104E</gtr:id><gtr:title>Structural basis for cell surface patterning through NetrinG-NGL interactions.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90d6514d22869015fa3a132781b28749"><gtr:id>90d6514d22869015fa3a132781b28749</gtr:id><gtr:otherNames>Seiradake E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>YKNeow4rEFS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD137493-46DF-49B2-B40B-9FB28F0D326A</gtr:id><gtr:title>Crystal structure of the GluR2 amino-terminal domain provides insights into the architecture and assembly of ionotropic glutamate receptors.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94cecf5eee5ee2651ba0267133ed5d73"><gtr:id>94cecf5eee5ee2651ba0267133ed5d73</gtr:id><gtr:otherNames>Clayton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>DdsnckJZ7YU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BC66C45-16B9-4C0D-8C10-2D57A15ECFC5</gtr:id><gtr:title>Copines-1, -2, -3, -6 and -7 show different calcium-dependent intracellular membrane translocation and targeting.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd259166c53003eca1f259dc3b1df87c"><gtr:id>bd259166c53003eca1f259dc3b1df87c</gtr:id><gtr:otherNames>Perestenko PV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>VdMueJNkanS</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U138197108</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>